

Obstructive Sleep Apnea - Pipeline Insight, 2021

<https://marketpublishers.com/r/OCE04CFC380DEN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: OCE04CFC380DEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Obstructive Sleep Apnea - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Obstructive Sleep Apnea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Obstructive Sleep Apnea Understanding

Obstructive Sleep Apnea: Overview

Obstructive sleep apnea (OSA) consists of episodes of partial or complete closure of the upper airway that occur during sleep and lead to breathing cessation (defined as a period of apnea or hypopnea > 10 seconds). Symptoms include excessive daytime sleepiness, restlessness, snoring, recurrent awakening, and morning headache. Diagnosis is based on sleep history and polysomnography. Treatment is with nasal continuous positive airway pressure, oral appliances, and, in refractory cases, surgery. Prognosis is good with treatment. Most cases remain undiagnosed and untreated and are often associated with hypertension, atrial fibrillation and other arrhythmias, heart failure, and injury or death due to motor vehicle crashes and other accidents resulting from hypersomnolence.

'Obstructive Sleep Apnea - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obstructive Sleep Apnea pipeline landscape is provided which includes the disease overview and Obstructive Sleep Apnea treatment guidelines. The assessment part of the report embraces, in depth Obstructive Sleep Apnea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obstructive Sleep Apnea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Obstructive Sleep Apnea R&D. The therapies under development are focused on novel approaches to treat/improve Obstructive Sleep Apnea.

Obstructive Sleep Apnea Emerging Drugs Chapters

This segment of the Obstructive Sleep Apnea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Obstructive Sleep Apnea Emerging Drugs

AD036: Apnimed

AD036, consisting of the norepinephrine reuptake inhibitor, atomoxetine, combined with the anti-muscarinic oxybutynin, was studied in a large Phase II clinical trial that included 140 patients with a broad range of OSA severity from moderate to very severe. AD036 improved multiple objective measures of OSA as well as OSA symptoms, providing proof-of-concept that an oral pharmacologic approach may have clinical benefit in patients with OSA.

THX-110: Therapix Biosciences

THX-110 is a drug candidate platform for the treatment of symptoms related to Tourette syndrome (TS), as well as Obstructive Sleep Apnea (OSA) and chronic pain. The THX-110 program takes a unique approach to cannabinoid formulation using the “Entourage Effect” hypothesis (i.e. in which Endocannabinoid system constituents work synergistically together). THX-110 is a proprietary combination drug based on dronabinol and PEA. PEA is a cannabinoid mimetic lipid molecule, which naturally occurs in various plant and animal sources.

Further product details are provided in the report.....

Obstructive Sleep Apnea: Therapeutic Assessment

This segment of the report provides insights about the different Obstructive Sleep Apnea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Obstructive Sleep Apnea

There are approx. 20+ key companies which are developing the therapies for Obstructive Sleep Apnea. The companies which have their Obstructive Sleep Apnea drug candidates in the most advanced stage, i.e. phase II include, Apnimed.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Obstructive Sleep Apnea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obstructive Sleep Apnea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obstructive Sleep Apnea drugs.

Obstructive Sleep Apnea Report Insights

Obstructive Sleep Apnea Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Obstructive Sleep Apnea Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Obstructive Sleep Apnea drugs?

How many Obstructive Sleep Apnea drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obstructive Sleep Apnea?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Obstructive Sleep Apnea therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Obstructive Sleep Apnea and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Apnimed

Therapix Biosciences

Eisai

Idorsia Pharmaceuticals

Takeda

Merck & Co

Taisho Pharmaceutical Co., Ltd.

Bayer

Janssen Pharmaceuticals

RespireRx Pharmaceuticals

Cortex Pharmaceuticals

Michael James Enterprises

Key Products

AD036

THX-110

Lemborexant

AD182

AD504

AD109

ACT-541468

TAK-925

Gefapixant

TS-142

BAY2586116

Seltorexant

Dronabinol low-dose

CX 1739

Dronabinol

Contents

Introduction

Executive Summary

Obstructive Sleep Apnea: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

AD036: Apnimed

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

ACT-541468: Idorsia Pharmaceuticals

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
Comparative Analysis
Obstructive Sleep Apnea Key Companies
Obstructive Sleep Apnea Key Products
Obstructive Sleep Apnea- Unmet Needs
Obstructive Sleep Apnea- Market Drivers and Barriers
Obstructive Sleep Apnea- Future Perspectives and Conclusion
Obstructive Sleep Apnea Analyst Views
Obstructive Sleep Apnea Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Obstructive Sleep Apnea
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Obstructive Sleep Apnea
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Obstructive Sleep Apnea - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/OCE04CFC380DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OCE04CFC380DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970